ELFABRIO CONCENTRATE FOR SOLUTION FOR INFUSION 2 MG/ML

CHIESI FARMACEUTICI S.P.A. (ITALY)🇸🇬 Health Sciences Authority

Approval Date: Feb 20, 2025
Approval ID: 448ebf0bd01b11d6
Company: CHIESI FARMACEUTICI S.P.A. (ITALY)
Type: Therapeutic

Approval Details

Approval Id: 448ebf0bd01b11d6
Drug Name: ELFABRIO CONCENTRATE FOR SOLUTION FOR INFUSION 2 MG/ML
Product Name: ELFABRIO CONCENTRATE FOR SOLUTION FOR INFUSION 2 MG/ML
Approval Number: SIN17186P
Approval Date: 2025-02-20
Registrant: ORIENT EUROPHARMA PTE LTD
Licence Holder: ORIENT EUROPHARMA PTE LTD
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: INFUSION, SOLUTION CONCENTRATE
Dosage: 5. DOSAGE AND ADMINISTRATION 5.1 Recommendations Prior to ELFABRIO Treatment Pretreatment <ul> <li>In enzyme replacement therapy (ERT)-experienced patients, if pretreatment with antihistamines, antipyretics, and/or corticosteroids was used prior to ERT administration, consider similar pretreatment with these medications before the first several ELFABRIO infusions. After 4 to 6 ELFABRIO infusions, a stepwise decrease in the pretreatment medication dose(s) and/or discontinuation of the pretreatment medication(s) may be considered if treatment with ELFABRIO was tolerated.</li> <li>In ERT-naïve patients, prior to ELFABRIO administration, pre-treating with antihistamines, antipyretics, and/or corticosteroids may be considered [see Warnings and Precautions (7.1, 7.2) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information].</li> </ul> Medical Support Appropriate medical support measures including cardiopulmonary resuscitation equipment should be readily available during ELFABRIO administration. 5.2 Recommended Dosage and Administration The recommended dosage of ELFABRIO, based on actual body weight, is 1 mg/kg administered by intravenous infusion every 2 weeks. The initial recommended ELFABRIO infusion rates for ERT-experienced or ERT-naïve patients are based on actual body weight [see Tables 1 and 2]. If one or more doses are missed, restart ELFABRIO treatment as soon as possible, maintaining the 2 week interval between infusions thereafter. Do not double a dose to compensate for a missed dose. 5.3 Administration Modifications Due to Hypersensitivity Reactions and/or Infusion-Associated Reactions In the event of a severe hypersensitivity reaction (e.g., anaphylaxis) or severe infusion- associated reaction (IAR), immediately discontinue ELFABRIO administration and initiate appropriate medical treatment. For additional recommendations in the event of a severe hypersensitivity reaction or IAR, see Warnings and Precautions (7.1, 7.2) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. In the event of a mild to moderate hypersensitivity reaction or a mild to moderate IAR, consider temporarily holding the infusion for 15 to 30 minutes or slowing the infusion rate by 25% to 50% [see Dosage and Administration (5.4)], and initiating appropriate medical treatment [see Warnings and Precautions (7.1, 7.2) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information]. <ul> <li>If symptoms persist despite holding or slowing the infusion, stop the infusion and monitor the patient. Consider re-initiating the infusion within 7 to 14 days at 25% to 50% of the rate at which the reaction occurred with appropriate pretreatment.</li> <li>If symptoms subside after holding the infusion, resume infusion at a 25% to 50% reduced rate as tolerated. Alternatively, if symptoms subside after slowing the infusion, complete infusion at the reduced rate as tolerated.</li> <li>Starting with the next infusion, increase the infusion rate by increments of 25% every third infusion as tolerated until the infusion rate at which the reaction occurred is reached. Closely monitor the patient.</li> </ul> 5.4 Preparation Instructions Use aseptic technique during preparation. Dilute ELFABRIO in the following manner: <ul> <li>Determine the number of ELFABRIO vials to be diluted based on actual body weight in kg and the recommended dose [see Dosage and Administration (5.2) and Dosage Forms and Strengths (3) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information]. Round the number of vials up to the next whole number.</li> <li>Remove the appropriate number of ELFABRIO vials from the refrigerator and allow the vials to sit for 15–30 minutes at room temperature 20°C to 25°C (68°F to 77°F) before use. Do not use an external heat source to heat the product because heat may damage the product.</li> <li>Visually inspect the solution in the vials for particulate matter and discoloration. The solution should be clear and colorless. Discard if the solution is discolored or if visible particulate matter is present.</li> <li>Dilute the supplied ELFABRIO solution required for a dose in 0.9% Sodium Chloride Injection to a total volume based on actual body weight specified in Tables 1 and 2 below.</li> <li>Prior to adding the volume of ELFABRIO required for the dose, remove the equal volume of 0.9% Sodium Chloride Injection from the infusion bag.</li> <li>Withdraw the volume of ELFABRIO required for the dose from the vials (discard any unused solution remaining in the vial).</li> <li>Inject the ELFABRIO solution directly into the 0.9% Sodium Chloride Injection solution through the port of the infusion bag. Do not inject in the airspace within the infusion bag.</li> <li>Gently invert infusion bag to mix the solution. Avoid vigorous shaking or agitation.</li> </ul> Administration Instructions Administer ELFABRIO as follows: <ul> <li>Use an in-line low protein-binding, 0.2 micron, in-line filter during administration.</li> <li>For the initial 4–6 infusions, infuse ELFABRIO using the infusion rates described in Table 1 for ERT-experienced patients and Table 2 for ERT-naïve patients.</li> <li>If a patient tolerates the initial 4–6 ELFABRIO infusions, the duration of every third infusion may be decreased in decrements of 30 minutes as tolerated. The minimum recommended infusion duration is 1.5 hours.</li> <li>At the end of the infusion, flush the line with 0.9% Sodium Chloride Injection using the same infusion rate as the one used for the last part of the ELFABRIO infusion.</li> <li>Do not infuse ELFABRIO in the same intravenous line with other products.</li> </ul> Table 1 presents the recommended infusion rates for the initial 4–6 ELFABRIO infusions based on actual body weight for ERT-experienced patients. Recommended Infusion Rate1 for ERT-Experienced Patients for the Initial 4–6 ELFABRIO Intravenous Infusions Based on Actual Body Weight <img src="/TGIF/Elfabrio-Table1.png" alt="Elfabrio Dosage Table 1" /> Table 2 presents the recommended infusion rates for the initial 4–6 ELFABRIO infusions based on actual body weight for ERT-naïve patients. <img src="/TGIF/Elfabrio-Table2.png" alt="Elfabrio Dosage Table 2" /> Administration of ELFABRIO to Patients Previously Treated with ERT with an Infusion Duration Over 3 Hours In patients previously treated with an ERT with an infusion duration over 3 hours: <ul> <li>Use the same infusion rate for the ELFABRIO infusion.</li> <li>May decrease the duration of every third infusion after the initial 4–6 ELFABRIO infusions in decrements of 30 minutes as tolerated. The recommended minimum infusion duration of the maintenance infusion is 1.5 hours.</li> </ul> Home Infusion Home administration under the supervision of a healthcare provider may be considered for patients who have reached an infusion duration that is tolerated well [see Dosage and Administration (5.1, 5.3)]. The decision to have a patient move to home infusion should be made after evaluation and recommendation by a healthcare provider. The infusion duration should remain constant for home administration and the duration should only be decreased in a healthcare facility. In case of a missed dose or delayed infusion, a healthcare provider should be contacted.
Route Of Administration: INTRAVENOUS
Indication Info: 4. INDICATION AND USAGE ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease.
Contraindications: 6 CONTRAINDICATIONS None.
Atc Code: A16AB20
Pharma Manufacturer Name: ORIENT EUROPHARMA PTE LTD
Company Detail Path: /organization/orient-europharma-pte-ltd

Active Ingredients

Pegunigalsidase alfa

2 mg/ml

Pegunigalsidase alfa

2 mg/ml

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Feb 20, 2025

Approval ID

448ebf0bd01b11d6

Type

Therapeutic

Back to HSA Approvals